CORCEPT THERAPEUTICS INC
Close on Oct 19, 2026
- Market cap
- $13.27B
- P/E (TTM)
- 266.9
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 29, 2026 | After market close | $256.10M | $0.36 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | After market close | $164.90M | $-0.30 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | After market close | $202.10M | $0.20 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | After market close | $207.60M | $0.16 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 31, 2025 | After market close | $194.40M | $0.29 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 5, 2025 | After market close | $157.20M | $0.17 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | After market close | $181.90M | $0.26 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | After market close | $182.50M | $0.41 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 29, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 1, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 15, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Jul 29, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue guidance | 2026 | $1.10B to $1.20B | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Corcept Therapeutics filed with the SEC
Corcept Announces Planned Leadership Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corcept Resubmits New Drug Application for Relacorilant
Other events · EX-99.1 to Form 8-K
Corcept Therapeutics Announces First Quarter Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli (relacorilant)
Other events · EX-99.1 to Form 8-K
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals
Other events · EX-99.1 to Form 8-K
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in
Other events · EX-99.1 to Form 8-K
Corcept Receives Complete Response Letter for Relacorilant
Other events · EX-99.1 to Form 8-K
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant
Other events · EX-99.1 to Form 8-K
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corcept Submits New Drug Application for Relacorilant
Other events · EX-99.1 to Form 8-K
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRIMARY ENDPOINT MET IN CORCEPTS PIVOTAL PHASE 3 ROSELLA TRIAL OF
Other events · EX-99.1 to Form 8-K
FDA FILES CORCEPTS NEW DRUG APPLICATION FOR RELACORILANT AS
Other events · EX-99.1 to Form 8-K
CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CORCEPT SUBMITS NEW DRUG APPLICATION FOR RELACORILANT
Other events · EX-99.1 to Form 8-K
CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS, POSITIVE RESULTS FROM PHASE 3 GRADIENT TRIAL IN PATIENTS WITH CUSHING’S SYNDROME
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99 to Form 8-K
CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CORCEPT THERAPEUTICS PROVIDES FINANCIAL UPDATE
Results of operations · Other events · EX-99.1 to Form 8-K
C OURT F INDS C ORCEPT T HERAPEUTICS
Other events · EX-99.1 to Form 8-K
CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
C ORCEPT T HERAPEUTICS A NNOUNCES P RELIMINARY
Other events · EX-99.1 to Form 8-K
C ORCEPT T HERAPEUTICS S ETTLES P ATENT
Other events · EX-99.1 to Form 8-K
CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corcept Therapeutics Announces Extension of
Other events · EX-99.1 to Form 8-K
CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K